Author: Editor

Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center discusses how to control rising drug prices without impacting the value of the drug at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center explains the optimal duration of adjuvant chemotherapy in colon cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center discusses the interventions to alleviate financial toxicity at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Philip Philip, MD of Karmanos Cancer Institute discusses duration of therapy and whether or not shorter treatments will have the same outcomes for patients with stage III colon cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Philip Philip, MD of Karmanos Cancer Institute discusses the use of lenvatinib in patients with unresectable hepatocellular carcinoma (HCC) at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Philip Philip, MD of Karmanos Cancer Institute discusses the possible benefits of the use of immunotherapy in gastrointestinal diseases at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Philip Philip, MD of Karmanos Cancer Institute gives his take on the use of capecitabine in biliary cancers at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Philip Philip, MD of Karmanos Cancer Institute discusses the impact of PEGPH20 on care of patients with metastatic pancreatic cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Daniel Petrylak, MD of Yale School of Medicine discusses which tests patients with urothelial carcinoma should receive as part of their cancer care at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Daniel Petrylak, MD of Yale School of Medicine discusses what’s next for patient with bladder cancer after checkpoint inhibition therapy at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Daniel Petrylak, MD of Yale School of Medicine discusses the role of checkpoint inhibition therapy in urothelial carcinoma cancer at the 2017 Annual Meeting Annual Meeting.

Daniel Petrylak, MD of Yale School of Medicine discusses whether or not prostate cancer guidelines should be updated based on the new results of the LATITUDE study. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses the collaboration between COTA and IBM Watson Health at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses the implications of healthcare and reimbursement reform on technologies and innovates at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses what tools do oncologists need as they move from fee for service to value based reimbursement at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses how healthcare reform and the move from volume to value progressing in oncology at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debra Patt, MD, MPH, MBA, VP of Texas Oncology explains what utilization management is and why it is important in cancer care at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses implementing an informatics-enabled oncology practice at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses the future of the 340B program, which requires pharmaceutical companies to provide outpatient drugs to eligible health care organizations significantly reduced prices. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses the importance of patrolling drug costs and reimbursements for Texas Oncology at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses why she has not been incorporating liquid biopsies into patient management at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses the collaboration between the Association of Community Cancer Centers (ACCC) and OCM and how ACCC is supporting other practices that are participating in OCM. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses the challenges and solutions Lancaster General Health is finding as it participates in OCM at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses the major themes coming out of Oncology Care Model (OCM) at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses how Oncology Care Model (OCM) is helping the health care system at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew Norden, MD of IBM Watson Health gives an overview of the data demonstrating clinical utility for Watson for Oncology (WFO) at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew Norden, MD of IBM Watson Health discusses future developments for IBM Watson at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew Norden, MD of IBM Watson Health discusses IBM Watson’s library of tumor types and what it takes to add a new tumor at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew Norden, MD of IBM Watson Health explains how the Watson for Clinical Trial Matching tool matches patients to clinical trials at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jeffrey Meyehardt, MD of Harvard Medical School discusses the use of vemurafenib in BRAF+ mutated metastatic colorectal cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jeffrey Meyehardt, MD of Harvard Medical School explains whether or not selective internal radiation therapy (SIRT) is effective in treating metastatic hepatocellular carcinoma (HCC) at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jeffrey Meyehardt, MD of Harvard Medical School discusses the optimal duration of therapy for patients with stage III colon cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jeffrey Meyehardt, MD of Harvard Medical School discusses how immunotherapy is being studied and implemented in the treatment of gastric and esophageal cancers at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses how he identifies and chooses the right patients for abiraterone and enzalutamide at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses whether or not AR-V7 is ready for prime time at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Christopher J. Logothetis, MD of MD Anderson Cancer Center compares the three trials, CHAARTED, STAMPEDE, and LATITUDE, and discusses how clinicians choose between chemotherapies for patients with prostate cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses the impact of cost with the introduction of abiraterone as standard of care for patients with prostate cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses why the LATITUDE study will be practice changing for the treatment of prostate cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Kathryn Kolibaba, MD of US Oncology Research discusses the general takeaways from the oral sessions on lymphoma presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Kathryn Kolibaba, MD of US Oncology Research discusses the MAGNIFY study and its impact on high-risk indolent NHL patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Kathryn Kolibaba, MD of US Oncology Research gives an overview of the results from the BRIGHT study and its impact on treatment for indolent non-hodgkin lymphoma patients. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Edward Kim, MD of Levine Cancer Institute discusses the use of immunotherapy combinations for future treatment of patients with lung cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Edward Kim, MD of Levine Cancer Institute discusses the use of gefitinib versus standard chemotherapy for patients with stage II-IIIA non-small cell lung cancer with an EGFR mutation. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Edward Kim, MD of Levine Cancer Institute explains how anti-PD-L1 and PD-1 therapies are being combined with chemotherapy and targeted therapies in treating lung cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Edward Kim, MD of Levine Cancer Institute discusses the biggest updates in lung cancer research, which include the breakthrough of immunotherapy and the approval of new biomarkers. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses the APHINITY trial and its impact on clinical practice and future treatment for breast cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses the differences and similarities between CDK 4/6 inhibitors at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses how immunotherapy is being studied and integrated into the treatment of metastatic breast cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses the impact of the MONARCH-2 trial on treating patients with metastatic ER+ breast cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Sundar Jagannath, MD of Icahn School of Medicine at Mount Sinai gives an overview of the most promising studies on myeloma presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.